
    
      French multicenter double-blind controlled parallel-group randomized clinical trial Phase IV
      assessing whether a hydrocortisone replacement therapy could increase the success rate of GC
      withdrawal at one year, in patients with Rheumatoid Arthritis in low disease activity or
      remission, in comparison to progressive decrease of GC (GC tapering).
    
  